Cerus Corp (CERS) Quote

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

CERS new 52 week low

$CERS Book Value Per Share (mrq) ONLY $0.65

Looks like CP using Intercept plasma will push the SP well over $7 and just could go over $20 if key metrics indicate a possible buy out. Since the closest competition Mirasol is now a non-starter with the FDA last week, CERS occupies a monopoly position. That is not to mention RBS approval in the next few years as well as the now released info that American Red Cross will not guarantee requested shipment fulfillment if Intercept is not stipulated. CERS now owns the market along with locked in distributors throughout the world. No brainer investment for the whole next decade. Even buying at $20 SP will be a 10 bagger in5 yeas or less. Probably less. Very long here.

Looking for entry, awesome growth and balance sheet, could be a good Covid play jmo

* * $CERS Video Chart 02-13-2020 * *

Link to Video - click here to watch the technical chart video

* * $CERS Video Chart 02-04-2020 * *

Link to Video - click here to watch the technical chart video

* * $CERS Video Chart 06-29-2019 * *

Link to Video - click here to watch the technical chart video

CERS been in this play for 2 months now...time to make some noise!!!

Longer term technical promise. http://stockcharts.com/public/1164099

From Berkshire Hathaway's - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2017.

Recent developments and highlights include:

*Reported record fourth quarter product revenue of $16.2 million, an increase of 60% compared to the
same period in the year prior.
*Established 2018 annual product revenue guidance of $51 million to $53 million, which would
represent a

17% to 22% increase over 2017 reported product revenue.

*Successfully met primary safety and efficacy endpoints in SPARC, Cerus’ European Phase 3 clinical trial *evaluating INTERCEPT red cell transfusions in thalassemia patients.
*Completed an underwritten public offering of common stock raising gross proceeds of $57.5 million.
*Advanced release assay for commercial manufacturing of the S303 compound used in the INTERCEPT
red blood cell system to enable H2 2018 CE Mark submission.

IMO it is up from here and a buy at $5.

NAVY Department worth more than today's 4 cent CERS SP rise. Description: Department of the Navy

Bureau of Medicine and Surgery

U.S. Naval Hospital Guam

US Naval Hospital Guam intends to award a sole-source drop-shipment contract under the authority of FAR 13, due to the only source available to meet the Government's needs, to Cerus Corporation, 2550 Stanwell Drive, Concord, CA 94520. Reference NAICS Code 325412. The following products will be procured: 0001. INTERCEPT Platelet Small Volume Processing Set, P/N INT2110B. Quantity: 8 Cases (2 cases to be delivered on March 2018, May 2018, July 2018, and Sep 2018). 0002. INTERCEPT Platelet Processing Set with Dual Storage Containers, P/N INT2510B. Quantity: 5 Cases (2 cases to be delivered on March 2018, 1 case to be delivered on May 2018, July 2018, and Sep 2018. This notice of intent is not a request for competitive proposals.

FULL INFO https://www.fbo.gov/spg/DON/BUMED/N68096/N6809618Q0008/listing.html

Time for a big thumbs up on that start!!

Shorts attacked it well today

Good new out yesterday after regarding CERS trials. Stock is steadily moving UP!!!

Yesterday, today and tomorrow!

* * $CERS Video Chart 11-03-17 * *

Link to Video - click here to watch the technical chart video

Big news!!!

Is this today's bio play?

What a joke!!!!!!!!!!!!!!!!!!!!!!! Played the Zika! Pump and now Dump!!!

* * $CERS Video Chart 08-08-17 * *

Link to Video - click here to watch the technical chart video

Employee buying?

you have to wait till tomorrow...

Are things turning around?

* * $CERS Video Chart 07-27-17 * *

Link to Video - click here to watch the technical chart video

The frustrating thing with this stock is whenever there is good news (as we had recently) the increase in the stock price is de minimis. However, whenever there is the hint of bad news, the stock price falls through the floor.

When is the red blood cell treatment going to be ready for FDA approval? There has been far too many delays on this and right now this stock needs to show profits (forget about narrowing losses). Also, any news if this company is the target of a merger or takeover?

* * $CERS Video Chart 06-07-17 * *

Link to Video - click here to watch the technical chart video

* * $CERS Video Chart 05-26-17 * *

Link to Video - click here to watch the technical chart video

I ran a 10-year chart on $CERS to find the bottom from a technical perspective: $0.60 on March 1, 2009.



Something doesn't gel with the commentary in the 8-k:

"...On May 23, 2017, Cerus Corporation (the "Company" or "Cerus") announced that it had received notification last week of a pending U.S. supply shortage of a platelet additive solution ("PAS") manufactured and sold by Fresenius Kabi Deutschland GmbH ("Fresenius Kabi"). The pending shortage is due to an unanticipated delay in U.S. Food and Drug Administration ("FDA") approval of a plastic component used in the manufacture of the PAS container following discontinuation of the original component by Fresenius Kabi's supplier. The shortage is expected to temporarily impact certain U.S. blood centers that utilize PAS to produce INTERCEPT platelets. Fresenius Kabi has stated that it is working with its suppliers and the FDA to resolve this delay and minimize any long-term disruption in supply. However, Cerus believes that the pending shortage could adversely affect INTERCEPT platelet production by impacted blood centers through year end. ..."

$CERS price decline also doesn't match the relatively small projected revenue declines: 4-12% depending on actuals.

"...As a result of the expected impact of the PAS supply disruption on INTERCEPT platelet production, the Company is updating its 2017 product revenue guidance to a range of $38 million to $46 million compared to the prior range of $43 million to $48 million. ..."

Yea looks like that this one is done for awhile

Every chart I see from the point the stock starts falling to where it starts gaining steam again is 2-4 months... but mainly 2-3 months... now it may take 6 months to gain the ground it lost back.. but the bottom is around 2-3 months....

Check the monthly charts. Every downtrend took about 6 months.

Even with the oversold RSI? I was watching to see when there'd be a turn in the price and sentiment short-term.

Longer-term, I agree based on the announced delays.

Thanks for the inputs :)

Price will drift downward for 6 months, then buy.

Do you see this company recovering?

Yea might buy to flip easy money this thing has a ways to go....fda acting the same as ever lol

Heading under $2.

Elk Creek Partners, LLC has filed a new 13G, reporting 5.17% ownership in $CERS - https://fintel.io/so/us/cers

Its lower. ..glad I sold went to penny mmj plays best move i could hsvr made

Waiting to buy CERS at 3.75 read my post April 4

I will buy back at 3.75 not highter

Hi Guys,

Looks like they took the recent earnings on the chin. And

bounced back.....This should run when if France, South Africa

launch and or FDA final goes into law.

Hi Guys,

Yes they are slow in marketing and sales. But this sell off will

reward much to those who hold for 2 plus years.

Action point.


FDA Blood safety guidelines issued for this year implementation

in 2018,

Sales of Incercept to France, Canada, Africa, and South America

Noted.

Hi Guys,

Looks like CERS issued some large bonus to key employees.

Looks bullish to me.

Earning after market closes on March 7, 2017.

Should test past highs!!!! And more. Several brokerage houses

have target prices $9-10.

With a lot more potential in the future!!!!

Hi Guys,

Really strange that CERS did not issue a press release with this detail study.

Something big must be up...........IMHO

Buying more here.

Excerpts from

http://onlinelibrary.wiley.com/doi/10.1111/trf.13993/full
See full text for abbreviations and context.

Given their rapid emergence and lack of predictability,
emerging pathogens challenge the current testing paradigm...

An alternate way to manage the continuous threat of
emerging infectious agents is the use of PI technologies
to proactively protect the blood supply and mitigate the
risk of TTIDs. PI = Pathogen Inactivation

The findings of this study are of particular importance
after the US FDA recommended in August 2016 to
1) test all donations collected with a licensed or investigational
individual donor NAT for ZIKV under an investigational
new drug application, 2) to implement pathogen reduction
technology for PLTs and plasma using FDA-approved
devices, or 3) to implement pathogen reduction technology
for whole blood or RBCs if an FDA-approved or
investigational device becomes available.

The amotosalen/UVA systems for plasma and PLTs were
approved by FDA in 2014 and were commercially available
when ZIKV emerged in the Americas and the INTERCEPT
Blood System for PLTs was implemented at the time of the
ZIKV crisis in Puerto Rico in February 2016 to safeguard
and maintain the availability of the blood supply on the island.[60]

The results of this study complement previous results[65]
and show that ZIKV can be inactivated in all blood components
(Table 3) using amotosalen/UVA for PLTs and plasma[41]
and S-303 and GSH for RBCs. The availability of broad spectrum
PI technologies for all blood components enables a new paradigm
for blood safety that can be used to maintain the ongoing
availability and safety of blood products in time of epidemics
with newly emerged and potentially susceptible pathogens.

A great reason to buy while the price is at the $4 mark.... but not for long!!

Hi Guys,

When this hit the wires we should see a good move upward.

http://onlinelibrary.wiley.com/doi/10.1111/trf.13993/full


Intercept tested on Zika infested blood; And removes from Red Blood Cells!!!!

No idea on a timeline. I've been day trading it for the past week or so. Movement has been pretty predictable between the teens and twenties.

I am long on this stock and will continue to hold - but it is frustrating that good news does not seem to move the stock up - and the slightest amount of bad news brings the price down precipitously.

This company needs to start generating profits - sooner rather than later - and the only thing that will move them toward profitability is getting their red blood cell treatment approved by the FDA. Any time frame for getting this accomplished? If this is not done soon, we may be at a depressed stock price for many years into the future.